期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CYP2C9/2C19基因多态性与苯妥英抗癫痫个体剂量差异的关系 被引量：3

暂未订购
导出
摘要 苯妥英(PHT)为临床上最常用的第一线抗癫痫药,但个体间对PHT代谢呈现较大差异。目前证实细胞色素氧化酶P450(CYP)2C9/19是体内参与PHT羟化的主要代谢酶。人群CYP2Cg/19遗传基因呈多态性,从而引起对PHT代谢个体间较大差异,部分人群对PHT呈强代谢(EM),另一部分人群呈弱代谢(PM),了解这些知识对临床用药十分重要。本文试对该方面内容进行综述。
作者 宋治 何楠
机构地区 中南大学湘雅三医院神经科 中南大学湘雅医学院遗传药理研究所
出处 《神经疾病与精神卫生》 2002年第3期148-150,共3页 Journal of Neuroscience and Mental Health
关键词 个体剂量差异 癫痫 苯妥英 细胞色素氧化酶P450 基因多态性
分类号 R742.1 [医药卫生—神经病学与精神病学] R965 [医药卫生—药理学]
  • 相关文献

参考文献22

  • 1Koch-Weser. The serum level approach to individualzation of drug dosage[J].Eur J Clin Pharmacol,1975,9:1-8.
  • 2Ludden TM,Allen JP,Valutsky WA,et al.Individualization of phenytoin dosage vegimens[J].Clin Pharmacol Ther,1977,21:287-293.
  • 3Yasumori T,chen LS,LIQh,et al.Human CYP2C-Mediated stereoseletive phenytoin hydroxylation in Janpanese:difference in chiral proference of CYP2C9 and CYP2C19[J].Biochem Pharmacol,1999,57:1 297-1 303.
  • 4De Morais SMF,Goldstein J,Xie HG,et al.Genetic analysis of the S-mephenytoin polymorphism in a Chinese population[J].Clin Pharmacol Ther,1995,58:404.
  • 5Kubota T,Chiba K,Ishizaki T.Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japenese population[J].Clin Pharmacol Ther,1996,60:661-666.
  • 6Roh HK,Dahl ML,Tybring G,et al.CYP2C19 genotype and phenotype determined by omeprazole in a Korean population[J].Pharmacogenetics,1996,6:547-551.
  • 7Aynacioglu AS,Sachse C,Bozkurt A,et al.Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population[J].Clin Pharmacol Ther,1999,66:185-192.
  • 8Herrlin K,Massele AY,Jande M,et al.Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype[J].Clin Pharmacol Ther,1998,64:391-401.
  • 9Nowak MP,Sellers EM,Tyndale RF.Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies[J].Clin Pharmacol Ther,1998,64:378-383.
  • 10Kaneko A,Bergqvist Y,Taleo G,et al.Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations[J].Pharmacogenetic,1999,9:317-326.

同被引文献64

  • 1牛春燕,罗金燕,王学勤,朱有玲.CYP2C19基因多态性对雷贝拉唑及埃索美拉唑抑酸效应的影响[J].中国临床医学,2004,11(6):1002-1004. 被引量：8
  • 2邢东亮,宋东奎,张莉蓉.膀胱癌患者细胞色素氧化酶P450 2C19基因多态性分析[J].郑州大学学报（医学版）,2006,41(2):285-287. 被引量：4
  • 3郑露,邵建国.CYP2C19的基因多态性与临床[J].第二军医大学学报,2007,28(11):1262-1265. 被引量：19
  • 4Nan He,Feng-Xiang Yan,Song-Lin Huang,Wei Wang,Zhou-Sheng Xiao,Zhao-Qian Liu,Hong-Hao Zhou. [J] 2002,European Journal of Clinical Pharmacology(1):15～18
  • 5Wroblewski B, Glenn MB. The cytochrome p-450 drug metabolizing enzyme system: an overview of potential clinically important drug interactions[J]. J Head Trauma Rebabil, 2002, 17(6): 571-574.
  • 6Wrighton SA, Stevens JC, Becker GW, et al. Isolation and characterization of human liver cytochrome P450 2C 19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation[J]. Arch Bioehem Biophys, 1993, 306(1): 240-245.
  • 7He N, Yan FX, Huang SL, et al. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population[J]. Eur J Clin Pharmacol, 2002, 58(1): 15-18.
  • 8Finta C, Zaphiropoulos PG. The human CYP2C locus: a prototype for intergenic and exon repetition splicing events[J]. Genomics, 2000, 63(3): 433-438.
  • 9De Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans[J]. J Biol Chem, 1994, 269(22): 15419-15422.
  • 10De Morais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)- mephenytoin metabolism in Japanese[J]. Mol Pharmacol, 1994, 46(4): 594-598.

引证文献3

二级引证文献43

神经疾病与精神卫生
2002年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部